IMMP IMMUTEP Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1506184 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: AUD | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 | FY20212021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 10.33M | 7.84M | 5.20M | 6.76M | 3.97M |
| R&D expense | 49.78M | 31.47M | 28.79M | 25.34M | 12.02M |
| SG&A expense | 8.64M | 8.85M | 8.68M | 7.21M | 6.28M |
| Interest expense | 37,078 | 30,594 | 20,401 | 92,430 | 9,825 |
| Pretax income | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
| Income tax | 0 | 0 | 0 | 34 | 33 |
| Net income | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
| EPS (basic) | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 |
| EPS (diluted) | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 |
| Weighted avg. shares (diluted) | 1.46B | 1.20B | 892.40M | 848.97M | 594.93M |
| Balance sheet | |||||
| Cash & equivalents | 67.41M | 161.79M | 123.42M | 80.00M | 60.59M |
| Short-term investments | 62.28M | 20.09M | 0 | — | — |
| Receivables | 9.87M | 7.35M | 7.95M | 8.37M | 6.12M |
| Current assets | 149.10M | 191.35M | 134.97M | 90.81M | 68.42M |
| PP&E, netmay include right-of-use assets (IFRS) | 63,458 | 63,145 | 83,144 | 37,933 | 40,891 |
| Total assets | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Current liabilities | 12.76M | 10.49M | 9.77M | 6.41M | 5.34M |
| Total liabilities | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Shareholders' equity | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
| Cash flow statement | |||||
| Operating cash flow | -62.05M | -34.82M | -35.36M | -30.23M | -17.64M |
| Capital expenditure | 45,769 | 29,215 | 82,735 | 22,914 | 15,601 |
| Free cash flow | -62.10M | -34.85M | -35.44M | -30.25M | -17.66M |
| Investing cash flow | -38.53M | -21.02M | -82,735 | -22,914 | -15,601 |
| Financing cash flow | -525,121 | 95.18M | 76.02M | 50.33M | 52.68M |
| Depreciation & amortization | 2.39M | 2.26M | 2.06M | 2.06M | 2.07M |
| Stock-based compensation | 1.16M | 1.80M | 2.00M | 1.49M | 1.70M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.